EUCTR2005-006182-14-IT
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies - Intravitreal bevacizumab
IVERSITA DEGLI STUDI DI UDINE0 sites30 target enrollmentFebruary 17, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- IVERSITA DEGLI STUDI DI UDINE
- Enrollment
- 30
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients with diffuse clinically significant diabetic macular edema CSDME ETDRS criteria either unresponsive to prior treatments laser or intravitreal triamcinolone or combined or very severe at initial presentation \- Patients with nonischemic branch retinal vein occlusion BRVO or central retinal vein occlusion CRVO and severe cystoid macular edema either unresponsive to prior treatments or persisting after 6 months since initial presentation \- Patients with age\-related macular degeneration AMD and subfoveal choroidal neovascularization CNV either unresponsive to prior PDT or unlikely to respond to PDT large subretinal hemorrhage, large PED, large minimally classic lesion, chorioretinal anastomosis \- Patients with age\-related macular degeneration AMD and stage II\-III retinal angiomatous proliferation RAP
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •EYE \- History of any ocular surgery within the previous 6 months \- Significant media opacities \- Macular ischemia at fluorescein angiography MEDICAL \- Chronic liver disease, clinical jaundice, and/or elevation of liver\-related laboratory results 2 times the upper limit of normal \- Chronic renal failure on dialysis \- Stroke \- Congestive heart failure or myocardial infarction \- Cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Intravitreal bevacizumab(Avastin) for macular edema secondary to uveitis: 1 year results of a prospective pilot studyMacular edema secondary to uveitis.Other specified retinal disordersIRCT138902113846N1Shiraz University of Medical Sciences30
Completed
Not Applicable
The intravitreal injection of Bevacizumab for retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000028770Department of Ophthalmology, Shiga University of Medical Science24
Completed
Not Applicable
ow dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathyProliferative diabetic retinopathyJPRN-UMIN000007482Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.60
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - NDViasual acuity lossMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2006-004320-36-ITAZIENDA OSPEDALIERA SENESE
Not yet recruiting
Not Applicable
Intravitreal Bevaxizumab injection for intraocular neovasculalization in childreretinopathy of prematurityJPRN-UMIN000007465Tokushima university hospital10